Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Current Liabilities: 2023-2025

  • Zhengye Biotechnology Holding's Total Current Liabilities was N/A to $18.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.6 million, marking a year-over-year change of. This contributed to the annual value of $18.6 million for FY2024, which is 12.42% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Total Current Liabilities is $18.6 million, which was up 0.13% from $18.6 million recorded in Q4 2024.
  • Zhengye Biotechnology Holding's Total Current Liabilities' 5-year high stood at $20.9 million during Q4 2023, with a 5-year trough of $18.6 million in Q4 2024.
  • For the 3-year period, Zhengye Biotechnology Holding's Total Current Liabilities averaged around $19.4 million, with its median value being $18.6 million (2025).
  • Data for Zhengye Biotechnology Holding's Total Current Liabilities shows a maximum YoY decreased of 10.77% (in 2024) over the last 5 years.
  • Over the past 3 years, Zhengye Biotechnology Holding's Total Current Liabilities (Quarterly) stood at $20.9 million in 2023, then decreased by 10.77% to $18.6 million in 2024, then reached $18.6 million in 2025.
  • Its Total Current Liabilities stands at $18.6 million for Q2 2025, versus $18.6 million for Q4 2024 and $20.9 million for Q4 2023.